JP7444864B2 - 肺投与によるうつ病の処置方法における使用のためのケタミン組成物 - Google Patents

肺投与によるうつ病の処置方法における使用のためのケタミン組成物 Download PDF

Info

Publication number
JP7444864B2
JP7444864B2 JP2021517252A JP2021517252A JP7444864B2 JP 7444864 B2 JP7444864 B2 JP 7444864B2 JP 2021517252 A JP2021517252 A JP 2021517252A JP 2021517252 A JP2021517252 A JP 2021517252A JP 7444864 B2 JP7444864 B2 JP 7444864B2
Authority
JP
Japan
Prior art keywords
composition
use according
ketamine
dose
esketamine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021517252A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022502429A (ja
JP2022502429A5 (https=
JPWO2020064748A5 (https=
Inventor
ヴィエチョレク，マチェイ
ヤノフスカ，シルヴィア
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Celon Pharma SA
Original Assignee
Celon Pharma SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celon Pharma SA filed Critical Celon Pharma SA
Publication of JP2022502429A publication Critical patent/JP2022502429A/ja
Publication of JP2022502429A5 publication Critical patent/JP2022502429A5/ja
Publication of JPWO2020064748A5 publication Critical patent/JPWO2020064748A5/ja
Application granted granted Critical
Publication of JP7444864B2 publication Critical patent/JP7444864B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
JP2021517252A 2018-09-28 2019-09-24 肺投与によるうつ病の処置方法における使用のためのケタミン組成物 Active JP7444864B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP18461615.9 2018-09-28
EP18461615.9A EP3628313B1 (en) 2018-09-28 2018-09-28 Ketamine composition for use in a method of treatment of depression by pulmonary administration
PCT/EP2019/075735 WO2020064748A1 (en) 2018-09-28 2019-09-24 Ketamine composition for use in a method of treatment of depression by pulmonary administration

Publications (4)

Publication Number Publication Date
JP2022502429A JP2022502429A (ja) 2022-01-11
JP2022502429A5 JP2022502429A5 (https=) 2022-09-28
JPWO2020064748A5 JPWO2020064748A5 (https=) 2022-09-28
JP7444864B2 true JP7444864B2 (ja) 2024-03-06

Family

ID=63713806

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021517252A Active JP7444864B2 (ja) 2018-09-28 2019-09-24 肺投与によるうつ病の処置方法における使用のためのケタミン組成物

Country Status (14)

Country Link
US (1) US11925607B2 (https=)
EP (3) EP3628313B1 (https=)
JP (1) JP7444864B2 (https=)
KR (1) KR102867739B1 (https=)
CN (1) CN113038941A (https=)
AU (1) AU2019349624B2 (https=)
BR (1) BR112021005687A2 (https=)
CA (1) CA3114325A1 (https=)
EA (1) EA202190724A1 (https=)
ES (2) ES3021221T3 (https=)
HU (2) HUE071303T2 (https=)
MX (1) MX2021003668A (https=)
PL (2) PL3628313T3 (https=)
WO (1) WO2020064748A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3505157T3 (pl) 2017-12-29 2022-04-11 Celon Pharma S.A. Kompozycja ketaminy w postaci suchego proszku do podawania dopłucnego w leczeniu depresji opornej na leczenie

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018515557A (ja) 2015-05-20 2018-06-14 ヤンセン ファーマシューティカ エヌ．ベー． うつ病を治療するための方法及びキット

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0009469D0 (en) * 2000-04-17 2000-06-07 Vectura Ltd Improvements in or relating to formalities for use in inhaler devices
GB0523031D0 (en) * 2005-11-11 2005-12-21 Yaupon Therapeutics Enhancement of morphine analgesia by s(-)-norketamine
WO2007111880A2 (en) 2006-03-22 2007-10-04 Mount Sinai School Of Medicine Intranasal administration of ketamine to treat depression
DE102007009888A1 (de) 2007-02-28 2008-09-04 Hermann, Holger Lars, Dr. Verwendung von S-(+)-Ketamin zur Behandlung von Depressionen
GB0908129D0 (en) * 2009-05-12 2009-06-24 Innovata Ltd Composition
PE20141906A1 (es) 2012-03-12 2014-12-05 Janssen Pharmaceutica Nv Esketamina para el tratamiento de la depresion refractaria al tratamiento o resistente al tratamiento
WO2014020155A1 (en) 2012-08-02 2014-02-06 Clinpharm Reform Gmbh Oral transmucosal adminstration forms of s-ketamine
PE20200404A1 (es) 2013-03-15 2020-02-26 Janssen Pharmaceutica Nv Composicion farmaceutica de clorhidrato de s-ketamina
CN116251084A (zh) 2013-03-15 2023-06-13 詹森药业有限公司 S-盐酸氯胺酮的药物组合物
CN106714789A (zh) * 2014-08-13 2017-05-24 詹森药业有限公司 用于治疗抑郁症的方法
CN106562952B (zh) * 2015-10-09 2020-06-09 江阴安博生物医药有限公司 氯胺酮在治疗重性抑郁障碍中的应用
PL3505157T3 (pl) * 2017-12-29 2022-04-11 Celon Pharma S.A. Kompozycja ketaminy w postaci suchego proszku do podawania dopłucnego w leczeniu depresji opornej na leczenie

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018515557A (ja) 2015-05-20 2018-06-14 ヤンセン ファーマシューティカ エヌ．ベー． うつ病を治療するための方法及びキット

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
"Safety and Pharmacokinetic Study of Inhaled Esketamine in Healthy Volunteers"，ClinicalTrials.gov，2018年07月12日，NCT03407872, p.1-7，https://clinicaltrials.gov/ct2/show/NCT03407872

Also Published As

Publication number Publication date
PL3628313T3 (pl) 2025-06-23
JP2022502429A (ja) 2022-01-11
HUE071649T2 (hu) 2025-09-28
EP3628313A1 (en) 2020-04-01
EP3856159A1 (en) 2021-08-04
MX2021003668A (es) 2021-08-19
EP4578505A3 (en) 2025-09-03
US11925607B2 (en) 2024-03-12
EP3856159B1 (en) 2025-03-12
ES3021221T3 (en) 2025-05-26
EA202190724A1 (ru) 2021-08-18
KR20210068465A (ko) 2021-06-09
HUE071303T2 (hu) 2025-08-28
AU2019349624B2 (en) 2025-08-28
PL3856159T3 (pl) 2025-06-16
EP3856159C0 (en) 2025-03-12
US20210353560A1 (en) 2021-11-18
BR112021005687A2 (pt) 2021-06-22
ES3028459T3 (en) 2025-06-19
EP3628313B1 (en) 2025-02-12
CA3114325A1 (en) 2020-04-02
EP4578505A2 (en) 2025-07-02
EP3628313C0 (en) 2025-02-12
KR102867739B1 (ko) 2025-10-13
WO2020064748A1 (en) 2020-04-02
AU2019349624A1 (en) 2021-04-29
CN113038941A (zh) 2021-06-25

Similar Documents

Publication Publication Date Title
US12440440B2 (en) Dry powder esketamine composition for use in the treatment of bipolar depression by pulmonary administration
CN107205936B (zh) 包含至少一种通过喷雾干燥得到的增加制剂稳定性的干粉的组合物
JP2021529771A (ja) クロモリンナトリウムおよびα−ラクトースの粉末製剤
US20250228779A1 (en) Method and composition for treating pulmonary fibrosis
AU2013334949A1 (en) Levodopa formulations for rapid relief of Parkinson's disease
JP7444864B2 (ja) 肺投与によるうつ病の処置方法における使用のためのケタミン組成物
EA044969B1 (ru) Композиция кетамина для применения в способе лечения депрессии путём ингаляционного введения
EA046690B1 (ru) Композиция кетамина в виде сухого порошка для применения при лечении депрессии ингаляционным путем
WO2022123607A1 (en) Pharmaceutical formulations of esketamine

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220916

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220916

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230822

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20230823

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231121

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20240126

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240222

R150 Certificate of patent or registration of utility model

Ref document number: 7444864

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150